Daily Archives: February 1, 2021
Study estimates vaccines against 10 pathogens prevented 37 million deaths in low- and middle-income countries in the last 20 years
1 Feb, 2021 | 01:44h | UTCCommentaries: Vaccines work: a reason for celebration and renewed commitment – The Lancet AND Study estimates that, without vaccination against 10 diseases, mortality in children under five would be 45% higher in low-income and middle-income countries – The Lancet AND Vaccines against 10 diseases prevented 37 million deaths in low- and middle-income countries in the last 20 years – London School of Hygiene & Tropical Medicine
Commentary on Twitter
NEW—Study estimates from 2000-2030, #vaccination against 10 major pathogens will have prevented 69 million deaths in low/middle-income countries (LMICs). Without vaccination, mortality in children under 5 would be 45% higher in LMICS. Read: https://t.co/S4JXOqdctU pic.twitter.com/MF8W25nDJJ
— The Lancet (@TheLancet) January 28, 2021
Seven technologies to watch in 2021
1 Feb, 2021 | 01:42h | UTCSeven technologies to watch in 2021 – Nature
WHO publishes new Essential Diagnostics List and urges countries to prioritize investments in testing
1 Feb, 2021 | 01:46h | UTCWHO Report: The selection and use of essential in vitro diagnostics – TRS 1031
Randomized trial: Conservative fluid management strategy vs. usual care in participants after cardiac surgery
1 Feb, 2021 | 01:39h | UTC
Association of dilated perivascular spaces with cognitive decline and incident dementia
1 Feb, 2021 | 01:38h | UTCThe Association of Dilated Perivascular Spaces with Cognitive Decline and Incident Dementia – Neurology (link to abstract – $ for full-text)
Commentaries: Large, Fluid-Filled Spaces Seen on Brain MRI Could Indicate Future Dementia – Diagnostic Imaging AND Perivascular Space Pathology Linked to Dementia in Seniors – HealthDay
Commentary on Twitter
.@GreenJournal: Severe perivascular space pathology in both centrum semiovale and basal ganglia was correlated with a greater risk of #dementia and #cognitive decline, regardless of other small vessel disease markers. #neurology @UNSW https://t.co/pHUhNBGpYw pic.twitter.com/dfaVvrTObx
— Neurology Today (@NeurologyToday) January 28, 2021
Decentralized clinical trials: Collaboration is needed to drive their adoption and impact
1 Feb, 2021 | 01:40h | UTCDecentralized clinical trials: Collaboration is needed to drive their adoption and impact – STAT
Blood test to detect psychogenic nonepileptic seizures shows promise
1 Feb, 2021 | 01:37h | UTCBlood Test to Detect Psychogenic Nonepileptic Seizures Shows Promise – Physician’s Weekly
Original study: Association of Epileptic and Non-epileptic Seizures and Changes in Circulating Plasma Proteins Linked to Neuroinflammation – Neurology (link to abstract – $ for full-text)
An analysis of contemporary oncology randomized clinical trials from low/middle-income vs. high-income countries
1 Feb, 2021 | 01:36h | UTCAn Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries – JAMA Oncology (free for a limited period)
ASCO Guideline: Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer
1 Feb, 2021 | 01:34h | UTC
Consensus statement recommends individualizing surveillance mammography for older patients after treatment for early-stage breast cancer
1 Feb, 2021 | 01:33h | UTCCommentaries: First Mammography Guidelines Released for Older Breast Cancer Survivors – Diagnostic Imaging AND New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older – The ASCO Post
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines
1 Feb, 2021 | 01:56h | UTCAdditional resources: COVID-19 Guidelines – Surviving Sepsis Campaign
Commentary on Twitter
New updates to the #SurvivingSepsis Campaign #COVID19 Guidelines! Includes new recommendations for therapeutics and defines severe vs critical COVID-19.
View the full update in @CritCareMed, more infographics, and recommendations table here: https://t.co/OUuOwGJCR4#SCCMSoMe pic.twitter.com/1RGckdvoIm
— SCCM (@SCCM) January 30, 2021
Analysis: J&J and Novavax Data
1 Feb, 2021 | 01:54h | UTCJ&J and Novavax Data – In the Pipeline
[Press release – not published yet] Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 trial
1 Feb, 2021 | 01:55h | UTCCommentaries: J&J’s one-shot COVID vaccine offers hope for faster protection – Nature AND Johnson & Johnson Executive Says Vaccine Works Where It Counts: Preventing Deaths – NPR AND Novavax’s COVID Vaccine Shows High Efficacy In Trials; J&J One-Dose Shot Less So – As Europe Feuds With AstraZeneca – Health Policy Watch AND Covid vaccine: Single-dose Johnson & Johnson jab is 66% effective – BBC AND Johnson & Johnson’s COVID-19 Vaccine Results Are Better Than They May Sound – TIME AND Expert reaction to Johnson & Johnson announcing that the single-shot Janssen COVID-19 vaccine candidate met primary endpoints in the interim analysis of its phase 3 ENSEMBLE Trial – Science Media Centre AND Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released – NIH News Releases AND J&J one-dose Covid vaccine is 66% effective, a weapon but not a knockout punch – STAT
SARS-CoV-2 vaccines and the growing threat of viral variants
1 Feb, 2021 | 01:50h | UTCSARS-CoV-2 Vaccines and the Growing Threat of Viral Variants – JAMA
How to redesign COVID vaccines so they protect against variants: lineages that can evade immunity are spurring vaccine makers to explore ways to redesign their shots
1 Feb, 2021 | 01:52h | UTCHow to redesign COVID vaccines so they protect against variants – Nature
See also: Vaccine 2.0: Moderna and other companies plan tweaks that would protect against new coronavirus mutations – Science (a few articles per month are free)
The most worrying mutations in five emerging coronavirus variants
1 Feb, 2021 | 01:50h | UTCThe Most Worrying Mutations in Five Emerging Coronavirus Variants – Scientific American
Analysis: Covid-19 pandemic and the social determinants of health
1 Feb, 2021 | 01:49h | UTCCovid-19 pandemic and the social determinants of health – The BMJ
Public health actions to control new SARS-CoV-2 variants
1 Feb, 2021 | 01:47h | UTCPublic health actions to control new SARS-CoV-2 variants – Cell
Commentary on Twitter (thread – click for more)
*Public health actions to control new SARS-CoV-2 variants*
Our paper just published in @CellCellPress w wonderful co-authors @NathanGrubaugh @firefoxx66 @JosephFauver & @mugecevik
We describe actions govts should urgently take to protect health.
— Dr Alexandra Phelan (@alexandraphelan) January 29, 2021
Explaining covid-19 performance: 10 factors might predict national responses
1 Feb, 2021 | 01:48h | UTCExplaining covid-19 performance: what factors might predict national responses? – The BMJ
Commentary on Twitter
The Global Health Security Index did not predict which countries would do well (or badly) in pandemic. Our new paper, led by @baumfran @bmj_latest gives 10 reasons why, & points to factors that are importanthttps://t.co/sVYGw1TFCR
— Martin McKee (@martinmckee) January 29, 2021